Medicine and Dentistry
Endometrial Cancer
100%
Krukenberg Tumor
74%
Gynecological Oncology
65%
Recurrent Disease
60%
Ovarian Cancer
57%
Neoplasm
54%
Disease
47%
CA-125
39%
In Vitro Fertilisation
38%
Cervical Cancer
30%
Overall Survival
29%
Carcinosarcoma
27%
Embryo Transfer
26%
Ovarian Tumor
25%
Hysterectomy
25%
Prognostic Factor
24%
Endometrium Carcinoma
24%
Follitropin
22%
Cervix
22%
Radiation Therapy
22%
Pelvis
20%
Placebo
20%
Niraparib
20%
Lymph Node
20%
Primary Peritoneal Carcinoma
19%
Polycystic Ovary Syndrome
19%
Carcinoma
19%
Ovulation Induction
18%
Diphtheria Toxin
17%
Recurrence Free Survival
17%
Progression Free Survival
17%
Pregnancy Rate
16%
Retrospective Study
16%
Adjuvant Therapy
15%
Adverse Event
15%
Oncology
15%
Topotecan
15%
Pharmacokinetics
15%
Human Menopausal Gonadotropin
15%
Hysteroscopy
14%
Polycystic Ovarian Syndrome
13%
Gonadotropin
13%
Malignant Neoplasm
13%
Surgery
12%
Long Term Survival
12%
Thrombocytosis
12%
Disease Specific Survival
12%
Maintenance Therapy
12%
Laparotomy
12%
Cancer
12%
Keyphrases
Endometrial Cancer
82%
Group Studies
60%
Gynecologic Oncology Group
60%
Israeli
57%
Primary Peritoneal Cancer
44%
Epithelial Ovarian Cancer
39%
In Vitro Fertilization
33%
Ovarian Cancer
32%
Overall Survival
29%
Israel
27%
Cervical Cancer
27%
CA-125 Levels
26%
Hysterectomy
25%
Ovulation Induction
25%
Uterine Carcinosarcoma
25%
Pharmacokinetics
25%
Tumor
25%
Ovarian Cancer Patients
24%
Phase II Study
24%
Follicle-stimulating Hormone
24%
Polycystic Ovary Syndrome
23%
Advanced Ovarian Cancer
23%
Cancer Patients
21%
Endometrial Carcinoma
20%
Carbohydrate Antigen 125 (CA125)
20%
ENGOT
20%
Diphtheria Toxin
17%
Gonadotropin-releasing Hormone
17%
Platinum Resistance
17%
Cervical Intraepithelial Neoplasia
16%
In Vitro Embryo Production
16%
Early-stage Cervical Cancer
16%
Prognostic Factors
15%
Patient Survival
15%
Placebo
15%
Laparotomy
15%
Chemotherapy
15%
Weekly Topotecan
15%
Carboplatin
15%
Paclitaxel
15%
Embryo Transfer
15%
Prognostic Significance
15%
Niraparib
15%
Platinum Sensitivity
14%
Epithelial Ovarian Carcinoma
14%
Tubal Carcinoma
14%
Gonadotropins
14%
Human Menopausal Gonadotropin
14%
Confidence Interval
14%
Recurrence-free Survival
14%